

Interaction Report**Report ID:****Date Produced:**

03 May 2025

Hepatology Treatment**Co-medications**

Bulevirtide

Ombitasvir/Paritaprevir/r + Dasabuvir

This report lists the summaries of potential interactions (i.e. "red", "amber" and "yellow" classifications) for the drugs in the table above.

Interactions with a "green" or "grey" classification (i.e. no clinically significant interaction or no clear data) have been checked and are listed at the end of this report, but summaries are not shown. Please note that some co-medications with a green classification may require dose adjustment due to hepatic impairment.

For full details of all interactions, see www.hepatology-druginteractions.org.

Description of the interactions**Drugs that should not be coadministered (RED)****Bulevirtide + Ombitasvir/Paritaprevir/r + Dasabuvir**

Bulevirtide is catabolized by peptidases and elimination occurs through binding to NTCP. Co-administration with NTCP inhibitors (e.g. ritonavir) is not recommended as it can alter bulevirtide elimination.